Through our research and discovery programs, we have identified, isolated, and characterized immunotherapeutics designed to manipulate the relationship between T effector cells and T regulatory cells. We have developed a unique understanding of how the immune system operates, both normally and in many disease states. Our research and development efforts are ongoing and have produced:
-
A database of over 100 potential targets, including components of signaling pathways, costimulatory molecules, cell surface molecules, and cytokines that selectively block or enhance the function of T effector cells and T regulatory cells
-
Screening assays (tests) for the identification of new T cell modulating therapies
-
Preclinical models that allow for direct validation of potential targets or analysis of the efficacy of T cell modulating therapies
-
Surrogate markers and prognostic indicators in preclinical models that allow us to rapidly identify the most appropriate dosing strategies
-
Novel agents directed at our and other targets.
We have identified and are validating multiple targets that we believe are relevant to T cell modulation and have filed several patent applications to protect these discoveries. We have also generated multiple monoclonal antibodies and fusion proteins against many of these targets.
